published meta-analysis   sensitivity analysis   studies

bamlanivimab/etesevimab in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsOPTIMISE-C19 (bamlanivimab-etesevimab vs casirivimab-imdevimab), 2021 1.22 [0.41; 3.64] 1.22[0.41; 3.64]OPTIMISE-C19 (bamlanivimab-etesevimab vs casirivimab-imdevimab), 202110%1,807NAnot evaluable hospitalizationdetailed resultsOPTIMISE-C19 (bamlanivimab-etesevimab vs casirivimab-imdevimab), 2021 1.03 [0.79; 1.34] 1.03[0.79; 1.34]OPTIMISE-C19 (bamlanivimab-etesevimab vs casirivimab-imdevimab), 202110%1,807NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-06-18 18:48 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 878 - roots T: 290